Mirati 516-005 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous NSCLC - Mercy Medical Center

Mirati 516-005 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous NSCLC

Posted on: January 30, 2020

This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy in combination with checkpoint inhibitor therapy. Being at least 18 years old and:

Inclusion Criteria
•Diagnosis of Non-Squamous Non-Small Cell Lung Cancer
•Receipt of prior first-line treatment with platinum-based chemotherapy in combination with PD-1/PD-L1 checkpoint inhibitor therapy
•Adequate bone marrow and organ function
•Candidate to receive docetaxel as second line therapy

Exclusion Criteria
•Uncontrolled brain metastases
•Tumors that have tested positive for EGFR, ROS1, ALK mutations, or ALK fusions
•Unacceptable toxicity with prior checkpoint inhibitor therapy
•Receipt of systemic anti-cancer therapy post checkpoint inhibitor therapy, other than maintenance chemotherapy in the first-line setting
•Impaired heart function

 

Leave a Reply

Mercy Medical Center | 1320 Mercy Drive NW, Canton, OH 44708 | info@cantonmercy.org
Contact Us | Careers | Privacy Policy | Copyright © 2017 Mercy Medical Center